Anecortave acetate.
This manuscript reviews the pharmacotherapeutics of the novel, angiostatic cortisene, anecortave acetate suspension, for the treatment of age-related macular degeneration. The chemistry, pharmacokinetics and pharmacodynamics of anecortave acetate are discussed, and the results of the multi-centre, randomised, controlled clinical trials for the treatment of subfoveal choroidal neovascularisation in age-related macular degeneration summarised. It also discusses ongoing clinical trials involving anecortave acetate for dry and wet age-related macular degeneration.
Bakri
Sophie J
SJ
Cole Eye Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk i3, Cleveland, OH 44195, USA.
Kaiser
Peter K
PK
D000818:Animals; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000737:chemistry
D015507:Drugs, Investigational; D011244:Pregnadienediols; C418047:anecortave acetate